{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:08:53Z","timestamp":1778911733865,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04097-5","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:21:23Z","timestamp":1778908883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the ocular use of chlorhexidine: an agent to remember in multidrug-resistant bacterial and fungal keratitis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4054-4868","authenticated-orcid":false,"given":"Mesut","family":"Arici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-8815","authenticated-orcid":false,"given":"Mukaddes Damla","family":"Ciftci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-3349","authenticated-orcid":false,"given":"Ozlem","family":"Barut Selver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"1","key":"4097_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/CMR.12.1.147","volume":"12","author":"G McDonnell","year":"1999","unstructured":"McDonnell G, Russell AD (1999) Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 12(1):147\u2013179. https:\/\/doi.org\/10.1128\/CMR.12.1.147","journal-title":"Clin Microbiol Rev"},{"key":"4097_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jtos.2022.04.003","volume":"25","author":"AR Kaufman","year":"2022","unstructured":"Kaufman AR, Tu EY (2022) Advances in the management of Acanthamoeba keratitis: a review of the literature and synthesized algorithmic approach. Ocul Surf 25:26\u201336. https:\/\/doi.org\/10.1016\/j.jtos.2022.04.003","journal-title":"Ocul Surf"},{"issue":"4","key":"4097_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41433-020-01339-3","volume":"35","author":"DSJ Ting","year":"2021","unstructured":"Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS (2021) Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond) 35(4):1084\u20131101. https:\/\/doi.org\/10.1038\/s41433-020-01339-3","journal-title":"Eye (Lond)"},{"issue":"4","key":"4097_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1444-0938.2007.00154.x","volume":"90","author":"L Brown","year":"2007","unstructured":"Brown L (2007) Resistance to ocular antibiotics: an overview. Clin Exp Optom 90(4):258\u2013262. https:\/\/doi.org\/10.1111\/j.1444-0938.2007.00154.x","journal-title":"Clin Exp Optom"},{"issue":"7","key":"4097_CR5","first-page":"1321","volume":"19","author":"TM Karpi\u0144ski","year":"2015","unstructured":"Karpi\u0144ski TM, Szkaradkiewicz AK (2015) Chlorhexidine--pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci 19(7):1321\u20131326","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9","key":"4097_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.2042-7158.1966.tb07935.x","volume":"18","author":"WB Hugo","year":"1966","unstructured":"Hugo WB, Longworth AR (1966) The effect of chlorhexidine on the electrophoretic mobility, cytoplasmic constituents, dehydrogenase activity and cell walls of Escherichia coli and Staphylococcus aureus. J Pharm Pharmacol 18(9):569\u2013578. https:\/\/doi.org\/10.1111\/j.2042-7158.1966.tb07935.x","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"4097_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3906\/sag-1503-140","volume":"46","author":"M Ekizo\u011flu","year":"2016","unstructured":"Ekizo\u011flu M, Sa\u011firo\u011flu M, Kili\u00e7 E, Has\u00e7elik AG (2016) An investigation of the bactericidal activity of chlorhexidine digluconateagainst multidrug-resistant hospital isolates. Turk J Med Sci 46(3):903\u2013909. https:\/\/doi.org\/10.3906\/sag-1503-140","journal-title":"Turk J Med Sci"},{"issue":"5","key":"4097_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","volume":"21","author":"EM Darby","year":"2023","unstructured":"Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA (2023) Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol 21(5):280\u2013295. https:\/\/doi.org\/10.1038\/s41579-022-00820-y","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4097_CR9","doi-asserted-by":"publisher","first-page":"106605","DOI":"10.1016\/j.ijantimicag.2022.106605","volume":"60","author":"X Zheng","year":"2022","unstructured":"Zheng X, Zhang X, Zhou B, Liu S, Chen W, Chen L, Zhang Y, Liao W, Zeng W, Wu Q, Xu C, Zhou T (2022) Clinical characteristics, tolerance mechanisms, and molecular epidemiology of reduced susceptibility to chlorhexidine among Pseudomonas aeruginosa isolated from a teaching hospital in China. Int J Antimicrob Agents 60(1):106605. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106605","journal-title":"Int J Antimicrob Agents"},{"key":"4097_CR10","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210123","author":"Y Nakipoglu","year":"2021","unstructured":"Nakipoglu Y (2021) Investigation of Chlorhexidine tolerance and its association with antibiotic resistance in clinical Gram-negative bacilli isolates. Clin Lab Stuttg. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210123","journal-title":"Clin Lab Stuttg"},{"issue":"3","key":"4097_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1089\/jop.2016.0053","volume":"33","author":"A Fern\u00e1ndez-Ferreiro","year":"2017","unstructured":"Fern\u00e1ndez-Ferreiro A, Santiago-Varela M, Gil-Mart\u00ednez M, Gonz\u00e1lez-Barcia M, Luaces-Rodr\u00edguez A, D\u00edaz-Tome V, Pardo M, M\u00e9ndez JB, Pi\u00f1eiro-Ces A, Rodr\u00edguez-Ares MT, Lamas MJ, Otero-Espinar FJ (2017) In vitro evaluation of the ophthalmic toxicity profile of chlorhexidine and propamidine isethionate eye drops. J Ocul Pharmacol Ther 33(3):202\u2013209. https:\/\/doi.org\/10.1089\/jop.2016.0053","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"4097_CR12","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41433-021-01768-8","volume":"36","author":"K Megha","year":"2022","unstructured":"Megha K, Sharma M, Sharma C, Gupta A, Sehgal R, Khurana S (2022) Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium. Eye (Lond) 36(10):1911\u20131917. https:\/\/doi.org\/10.1038\/s41433-021-01768-8","journal-title":"Eye (Lond)"},{"issue":"9","key":"4097_CR13","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1167\/iovs.13-11990","volume":"54","author":"CS Mafra","year":"2013","unstructured":"Mafra CS, Carrijo-Carvalho LC, Chudzinski-Tavassi AM, Taguchi FM, Foronda AS, Carvalho FR, de Freitas D (2013) Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity. Invest Ophthalmol Vis Sci 54(9):6363\u20136372. https:\/\/doi.org\/10.1167\/iovs.13-11990","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"4097_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/aos.16684","volume":"102","author":"R Hadad","year":"2024","unstructured":"Hadad R, Hedengran A, Barnils A, Petrovski G, Cvenkel B, Utheim TP, Dartt DA, Heegaard S, Kolko M (2024) Effect of chlorhexidine, povidone-iodine and Betadine antiseptic eye drops on cultured human conjunctival goblet cell survival. Acta Ophthalmol 102(7):773\u2013778. https:\/\/doi.org\/10.1111\/aos.16684","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"4097_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/DSS.0000000000000822","volume":"43","author":"KD Steinsapir","year":"2017","unstructured":"Steinsapir KD, Woodward JA (2017) Chlorhexidine keratitis: Safety of Chlorhexidine as a facial antiseptic. Dermatol Surg 43(1):1\u20136. https:\/\/doi.org\/10.1097\/DSS.0000000000000822","journal-title":"Dermatol Surg"},{"issue":"6","key":"4097_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/02713683.2018.1447674","volume":"43","author":"L Shi","year":"2018","unstructured":"Shi L, Stachon T, Seitz B, Wagenpfeil S, Langenbucher A, Szentm\u00e1ry N (2018) The effect of antiamoebic agents on viability, proliferation and migration of human epithelial cells, keratocytes and endothelial cells, in vitro. Curr Eye Res 43(6):725\u2013733. https:\/\/doi.org\/10.1080\/02713683.2018.1447674","journal-title":"Curr Eye Res"},{"issue":"118","key":"4097_CR17","first-page":"21","volume":"36","author":"AHA Mohamed-Ahmed","year":"2023","unstructured":"Mohamed-Ahmed AHA, Picken CAR, Kuguminkiriza D (2023) How to prepare chlorhexidine eye drops. Community Eye Health J 36(118):21\u201322","journal-title":"Community Eye Health J"},{"issue":"1","key":"4097_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00003226-199801000-00002","volume":"17","author":"TD Lindquist","year":"1998","unstructured":"Lindquist TD (1998) Treatment of Acanthamoeba keratitis. Cornea 17(1):11\u201316. https:\/\/doi.org\/10.1097\/00003226-199801000-00002","journal-title":"Cornea"},{"issue":"4","key":"4097_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ajo.2009.06.009","volume":"148","author":"JK Dart","year":"2009","unstructured":"Dart JK, Saw VP, Kilvington S (2009) Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 148(4):487-499.e2. https:\/\/doi.org\/10.1016\/j.ajo.2009.06.009","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4097_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archopht.124.6.923","volume":"124","author":"W Mathers","year":"2006","unstructured":"Mathers W (2006) Use of higher medication concentrations in the treatment of Acanthamoeba keratitis. Arch Ophthalmol 124(6):923. https:\/\/doi.org\/10.1001\/archopht.124.6.923","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"4097_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/09286589709115721","volume":"4","author":"MR Rahman","year":"1997","unstructured":"Rahman MR, Minassian DC, Srinivasan M, Martin MJ, Johnson GJ (1997) Trial of chlorhexidine gluconate for fungal corneal ulcers. Ophthalmic Epidemiol 4(3):141\u2013149. https:\/\/doi.org\/10.3109\/09286589709115721","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"4097_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2007.08.040","volume":"145","author":"N Lim","year":"2008","unstructured":"Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TR, Ficker L (2008) Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol 145(1):130\u2013135. https:\/\/doi.org\/10.1016\/j.ajo.2007.08.040","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"4097_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0161-6420(99)90169-0","volume":"106","author":"P Kosrirukvongs","year":"1999","unstructured":"Kosrirukvongs P, Wanachiwanawin D, Visvesvara GS (1999) Treatment of Acanthamoeba keratitis with chlorhexidine. Ophthalmology 106(4):798\u2013802. https:\/\/doi.org\/10.1016\/S0161-6420(99)90169-0","journal-title":"Ophthalmology"},{"issue":"3","key":"4097_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/jop.2006.81","volume":"23","author":"P Bu","year":"2007","unstructured":"Bu P, Riske PS, Zaya NE, Carey R, Bouchard CS (2007) A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin\/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. J ocul pharmacol ther off j Assoc Ocul Pharmacol Ther 23(3):213\u2013220. https:\/\/doi.org\/10.1089\/jop.2006.81","journal-title":"J ocul pharmacol ther off j Assoc Ocul Pharmacol Ther"},{"key":"4097_CR25","doi-asserted-by":"publisher","first-page":"741863","DOI":"10.3389\/fmicb.2021.741863","volume":"12","author":"KA Gr\u00e4nicher","year":"2021","unstructured":"Gr\u00e4nicher KA, Karygianni L, Attin T, Thurnheer T (2021) Low concentrations of chlorhexidine inhibit the formation and structural integrity of enzyme-treated multispecies oral biofilms. Front Microbiol 12:741863. https:\/\/doi.org\/10.3389\/fmicb.2021.741863","journal-title":"Front Microbiol"},{"issue":"12","key":"4097_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jamaophthalmol.2015.3888","volume":"133","author":"PA Asbell","year":"2015","unstructured":"Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW (2015) Antibiotic resistance among ocular pathogens in the united states: five-year results from the antibiotic resistance monitoring in ocular microorganisms (ARMOR) surveillance study. JAMA ophthalmol 133(12):1445\u20131454. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.3888","journal-title":"JAMA ophthalmol"},{"issue":"11","key":"4097_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamaophthalmol.2016.3283","volume":"134","author":"D Van Tyne","year":"2016","unstructured":"Van Tyne D, Ciolino JB, Wang J, Durand ML, Gilmore MS (2016) Novel phagocytosis-resistant extended-spectrum \u03b2-lactamase-producing Escherichia coli from keratitis. JAMA ophthalmol 134(11):1306\u20131309. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.3283","journal-title":"JAMA ophthalmol"},{"issue":"5","key":"4097_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamaophthalmol.2024.0259","volume":"142","author":"FE Tribin","year":"2024","unstructured":"Tribin FE, Lieux C, Maestre-Mesa J, Durkee H, Krishna K, Chou B, Neag E, T\u00f3thov\u00e1 JD, Martinez JD, Flynn HW Jr, Parel JM, Miller D, Amescua G (2024) Clinical features and treatment outcomes of carbapenem-resistant Pseudomonas aeruginosa keratitis. JAMA ophthalmol 142(5):407\u2013415. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.0259","journal-title":"JAMA ophthalmol"},{"issue":"6","key":"4097_CR29","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/bjophthalmol-2021-320203","volume":"107","author":"S Sahoo","year":"2023","unstructured":"Sahoo S, Alluri H, Mitra S, Priyadarshini S, Sahu SK, Mohanty A, Das S (2023) Multidrug-resistant keratitis: challenging yet manageable. Br J Ophthalmol 107(6):769\u2013773. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320203","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4097_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/bjophthalmol-2016-308487","volume":"101","author":"P Lalitha","year":"2017","unstructured":"Lalitha P, Manoharan G, Karpagam R, Prajna NV, Srinivasan M, Mascarenhas J, Das M, Porco TC, Lietman TM, Cevallos V, Keenan JD (2017) Trends in antibiotic resistance in bacterial keratitis isolates from South India. Br J Ophthalmol 101(2):108\u2013113. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308487","journal-title":"Br J Ophthalmol"},{"key":"4097_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/OPTH.S181997","volume":"14","author":"S Egrilmez","year":"2020","unstructured":"Egrilmez S, Yildirim-Theveny \u015e (2020) Treatment-resistant bacterial keratitis: challenges and solutions. Clinical ophthalmol (Auckl, NZ) 14:287\u2013297. https:\/\/doi.org\/10.2147\/OPTH.S181997","journal-title":"Clinical ophthalmol (Auckl, NZ)"},{"issue":"8","key":"4097_CR32","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jcrs.2007.04.015","volume":"33","author":"V Jhanji","year":"2007","unstructured":"Jhanji V, Sharma N, Satpathy G, Titiyal J (2007) Fourth-generation fluoroquinolone-resistant bacterial keratitis. J Cataract Refract Surg 33(8):1488\u20131489. https:\/\/doi.org\/10.1016\/j.jcrs.2007.04.015","journal-title":"J Cataract Refract Surg"},{"issue":"16","key":"4097_CR33","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1016\/j.bpj.2021.06.027","volume":"120","author":"M Rzycki","year":"2021","unstructured":"Rzycki M, Drabik D, Szostak-Paluch K, Hanus-Lorenz B, Kraszewski S (2021) Unraveling the mechanism of octenidine and chlorhexidine on membranes: Does electrostatics matter? Biophys J 120(16):3392\u20133408. https:\/\/doi.org\/10.1016\/j.bpj.2021.06.027","journal-title":"Biophys J"},{"issue":"11","key":"4097_CR34","first-page":"664","volume":"11","author":"N Geffen","year":"2009","unstructured":"Geffen N, Norman G, Kheradiya NS, Assia EI (2009) Chlorhexidine gluconate 0.02% as adjunct to primary treatment for corneal bacterial ulcers. Isr Med Assoc J 11(11):664\u2013668","journal-title":"Isr Med Assoc J"},{"key":"4097_CR35","doi-asserted-by":"publisher","DOI":"10.57073\/001c.8418","author":"L Lu","year":"2023","unstructured":"Lu L, Shen A, DeBoer C, Mahajan V, Lin C, Rose-Nussbaumer J (2023) Case report: multidrug-resistant Pseudomonas keratitis and sequential endophthalmitis treated with chlorhexidine and piperacillin-tazobactam. J EuCornea. https:\/\/doi.org\/10.57073\/001c.8418","journal-title":"J EuCornea"},{"issue":"2","key":"4097_CR36","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.clae.2024.102124","volume":"47","author":"M Sara","year":"2024","unstructured":"Sara M, Yasir M, Kalaiselvan P, Hui A, Kuppusamy R, Kumar N, Chakraborty S, Yu TT, Wong EHH, Molchanova N, Jenssen H, Lin JS, Barron AE, Willcox M (2024) The activity of antimicrobial peptoids against multidrug-resistant ocular pathogens. Contact Lens Anterior Eye 47(2):102124. https:\/\/doi.org\/10.1016\/j.clae.2024.102124","journal-title":"Contact Lens Anterior Eye"},{"issue":"1","key":"4097_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ceo.13345","volume":"47","author":"AP Ong","year":"2019","unstructured":"Ong AP, Angbue Te N, Zagora SL, Symes RJ, Yates W, Chang AA, McCluskey PJ, Simunovic MP (2019) Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora. Clin Exp Ophthalmol 47(1):57\u201362. https:\/\/doi.org\/10.1111\/ceo.13345","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"4097_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0161-642(01)00899-5","volume":"109","author":"TA Ciulla","year":"2002","unstructured":"Ciulla TA, Starr MB, Masket S (2002) Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 109(1):13\u201324. https:\/\/doi.org\/10.1016\/s0161-642(01)00899-5","journal-title":"Ophthalmology"},{"issue":"1","key":"4097_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12886-018-0844-9","volume":"18","author":"NJ Gili","year":"2018","unstructured":"Gili NJ, Noren T, T\u00f6rnquist E, Crafoord S, B\u00e4ckman A (2018) Preoperative preparation of eye with chlorhexidine solution significantly reduces bacterial load prior to 23-gauge vitrectomy in Swedish health care. BMC Ophthalmol 18(1):167. https:\/\/doi.org\/10.1186\/s12886-018-0844-9","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"4097_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archopht.1980.01020040125020","volume":"98","author":"K Green","year":"1980","unstructured":"Green K, Livingston V, Bowman K, Hull DS (1980) Chlorhexidine effects on corneal epithelium and endothelium. Arch Ophthalmol 98(7):1273\u20131278. https:\/\/doi.org\/10.1001\/archopht.1980.01020040125020","journal-title":"Arch Ophthalmol"},{"key":"4097_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/OPTO.S235679","volume":"13","author":"CS Bradley","year":"2021","unstructured":"Bradley CS, Sicks LA, Pucker AD (2021) Common ophthalmic preservatives in soft contact lens care products: benefits, complications, and a comparison to non-preserved solutions. Clin Optom 13:271\u2013285. https:\/\/doi.org\/10.2147\/OPTO.S235679","journal-title":"Clin Optom"},{"issue":"4","key":"4097_CR42","doi-asserted-by":"publisher","first-page":"CD004241","DOI":"10.1002\/14651858.CD004241.pub4","volume":"2015","author":"NV FlorCruz","year":"2015","unstructured":"FlorCruz NV, Evans JR (2015) Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2015(4):CD004241. https:\/\/doi.org\/10.1002\/14651858.CD004241.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4097_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/02713683.2019.1652916","volume":"45","author":"Z Kunt","year":"2020","unstructured":"Kunt Z, Ya\u011fmur M, Kandemir H, Harbiyeli I, Erdem E, Kalkanc\u0131 A, De Hoog GS, Ilkit M (2020) In vitro efficacy of chlorhexidine and a riboflavin\/UVA combination on fungal agents of keratitis. Curr Eye Res 45(1):7\u201311. https:\/\/doi.org\/10.1080\/02713683.2019.1652916","journal-title":"Curr Eye Res"},{"issue":"8","key":"4097_CR44","doi-asserted-by":"publisher","first-page":"e02669\u201318","DOI":"10.1128\/AAC.02669-18","volume":"63","author":"C Oliveira Dos Santos","year":"2019","unstructured":"Oliveira Dos Santos C, Kolwijck E, van der Lee HA, Tehupeiory-Kooreman MC, Al-Hatmi AMS, Matayan E, Burton MJ, Eggink CA, Verweij PE (2019) In vitro activity of chlorhexidine compared with seven antifungal agents against 98 Fusarium isolates recovered from fungal keratitis patients. Antimicrob Agents Chemother 63(8):e02669-18. https:\/\/doi.org\/10.1128\/AAC.02669-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4097_CR45","doi-asserted-by":"publisher","first-page":"e000698","DOI":"10.1136\/bmjophth-2020-000698","volume":"6","author":"S Arunga","year":"2021","unstructured":"Arunga S, Mbarak T, Ebong A, Mwesigye J, Kuguminkiriza D, Mohamed-Ahmed AHA, Hoffman JJ, Leck A, Hu V, Burton M (2021) Chlorhexidine gluconate 0.2% as a treatment for recalcitrant fungal keratitis in Uganda: a pilot study. BMJ Open Ophthalmol 6(1):e000698. https:\/\/doi.org\/10.1136\/bmjophth-2020-000698","journal-title":"BMJ Open Ophthalmol"},{"key":"4097_CR46","doi-asserted-by":"publisher","first-page":"1532289","DOI":"10.3389\/fcimb.2025.1532289","volume":"15","author":"M Kang","year":"2025","unstructured":"Kang M, Wu Y, Shi Q, Wang Z, Zhang Y, Chen K, Xu X, Zhou M, Liang Q, Lu X (2025) Antifungal susceptibility and clinical efficacy of chlorhexidine combined with topical ophthalmic medications against Fusarium species isolated from corneal samples. Front Cell Infect Microbiol 15:1532289. https:\/\/doi.org\/10.3389\/fcimb.2025.1532289","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"4097_CR47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ophtha.2021.12.004","volume":"129","author":"JJ Hoffman","year":"2022","unstructured":"Hoffman JJ, Yadav R, Sanyam SD, Chaudhary P, Roshan A, Singh SK, Singh SK, Mishra SK, Arunga S, Hu VH, Macleod D, Leck A, Burton MJ (2022) Topical Chlorhexidine 0.2% versus topical Natamycin 5% for the treatment of fungal keratitis in Nepal: a randomized controlled noninferiority trial. Ophthalmology 129(5):530\u2013541. https:\/\/doi.org\/10.1016\/j.ophtha.2021.12.004","journal-title":"Ophthalmology"},{"issue":"3","key":"4097_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"V Gote","year":"2019","unstructured":"Gote V, Sikder S, Sicotte J, Pal D (2019) Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther 370(3):602\u2013624. https:\/\/doi.org\/10.1124\/jpet.119.256933","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4097_CR49","doi-asserted-by":"publisher","first-page":"CD010792","DOI":"10.1002\/14651858.CD010792.pub2","volume":"2015","author":"M Alkharashi","year":"2015","unstructured":"Alkharashi M, Lindsley K, Law HA, Sikder S (2015) Medical interventions for Acanthamoeba keratitis. Cochrane Database Syst Rev 2015(2):CD010792. https:\/\/doi.org\/10.1002\/14651858.CD010792.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4097_CR50","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1128\/AAC.01123-15","volume":"60","author":"Y Aqeel","year":"2015","unstructured":"Aqeel Y, Siddiqui R, Anwar A, Shah MR, Khan NA (2015) Gold nanoparticle conjugation enhances the antiacanthamoebic effects of chlorhexidine. Antimicrob Agents Chemother 60(3):1283\u20131288. https:\/\/doi.org\/10.1128\/AAC.01123-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4097_CR51","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1167\/iovs.18-25003","volume":"59","author":"G Gomart","year":"2018","unstructured":"Gomart G, Denis J, Bourcier T, Dory A, Abou-Bacar A, Candolfi E, Sauer A (2018) In vitro amoebicidal activity of titanium dioxide\/UV-A combination against Acanthamoeba. Invest Ophthalmol Vis Sci 59(11):4567\u20134571. https:\/\/doi.org\/10.1167\/iovs.18-25003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"4097_CR52","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1021\/acs.molpharmaceut.0c00140","volume":"17","author":"MG Hewitt","year":"2020","unstructured":"Hewitt MG, Morrison PWJ, Boostrom HM, Morgan SR, Fallon M, Lewis PN, Whitaker D, Brancale A, Varricchio C, Quantock AJ, Burton MJ, Heard CM (2020) In vitro topical delivery of chlorhexidine to the cornea: Enhancement using drug-loaded contact lenses and \u03b2-cyclodextrin complexation, and the importance of simulating tear irrigation. Mol Pharm 17(4):1428\u20131441. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00140","journal-title":"Mol Pharm"},{"issue":"3","key":"4097_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0022-3549(15)00193-8","volume":"105","author":"P Paradiso","year":"2016","unstructured":"Paradiso P, Serro AP, Saramago B, Cola\u00e7o R, Chauhan A (2016) Controlled release of antibiotics from vitamin E-loaded silicone-hydrogel contact lenses. J Pharm Sci 105(3):1164\u20131172. https:\/\/doi.org\/10.1016\/S0022-3549(15)00193-8","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"4097_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2016.04.075","volume":"509","author":"I Heredero-Bermejo","year":"2016","unstructured":"Heredero-Bermejo I, S\u00e1nchez-Nieves J, Soliveri J, G\u00f3mez R, de la Mata FJ, Copa-Pati\u00f1o JL, P\u00e9rez-Serrano J (2016) In vitro anti-Acanthamoeba synergistic effect of chlorhexidine and cationic carbosilane dendrimers against both trophozoite and cyst forms. Int J Pharm 509(1\u20132):1\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.075","journal-title":"Int J Pharm"},{"key":"4097_CR55","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijpharm.2018.12.016","volume":"556","author":"A Cucina","year":"2019","unstructured":"Cucina A, Filali S, Risler A, Febvay C, Salmon D, Pivot C, Pelandakis M, Pirot F (2019) Dual 0.02% chlorhexidine digluconate - 0.1% disodium EDTA loaded thermosensitive ocular gel for Acanthamoeba keratitis treatment. Int J Pharm 556:330\u2013337. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.12.016","journal-title":"Int J Pharm"},{"issue":"7","key":"4097_CR56","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/pharmaceutics12070642","volume":"12","author":"C Caruso","year":"2020","unstructured":"Caruso C, Porta A, Tosco A, Eletto D, Pacente L, Bartollino S, Costagliola C (2020) A novel vitamin E TPGS-based formulation enhances chlorhexidine bioavailability in corneal layers. Pharmaceutics 12(7):642. https:\/\/doi.org\/10.3390\/pharmaceutics12070642","journal-title":"Pharmaceutics"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04097-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:21:25Z","timestamp":1778908885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4097"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04097-5","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"233"}}